Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (321-330 of 440) with videos related to

Pageof 44
Sort By:
Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.
The Lancet. Oncology|December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
British Journal of Haematology|July 5, 2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phaseDisni Muringampurath-John, David L Jaye, Christopher R Flowers, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Blood Cancer Journal|May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesionsDenis J Ohlstrom, Marina E Michaud, Mojtaba Bakhtiari, et al.
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.
Pageof 44

Showing results (321-330 of 440) with videos related to

Sort By:
Pageof 44
Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.
The Lancet. Oncology|December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
British Journal of Haematology|July 5, 2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phaseDisni Muringampurath-John, David L Jaye, Christopher R Flowers, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Blood Cancer Journal|May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesionsDenis J Ohlstrom, Marina E Michaud, Mojtaba Bakhtiari, et al.
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.
Pageof 44